These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 20951804)

  • 1. Antimicrobial and non-antimicrobial tetracyclines in human cancer trials.
    Richards C; Pantanowitz L; Dezube BJ
    Pharmacol Res; 2011 Feb; 63(2):151-6. PubMed ID: 20951804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemically modified non-antimicrobial tetracyclines are multifunctional drugs against advanced cancers.
    Lokeshwar BL
    Pharmacol Res; 2011 Feb; 63(2):146-50. PubMed ID: 21093590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tetracycline inhibition and the cellular source of collagenase in gingival crevicular fluid in different periodontal diseases. A review article.
    Ingman T; Sorsa T; Suomalainen K; Halinen S; Lindy O; Lauhio A; Saari H; Konttinen YT; Golub LM
    J Periodontol; 1993 Feb; 64(2):82-8. PubMed ID: 8433257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Introduction and background.
    Golub LM
    Pharmacol Res; 2011 Feb; 63(2):99-101. PubMed ID: 20937387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The nonantimicrobial properties of tetracycline for the treatment of periodontal disease.
    Vernillo AT; Ramamurthy NS; Golub LM; Rifkin BR
    Curr Opin Periodontol; 1994; ():111-8. PubMed ID: 8032451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Host modulation with tetracyclines and their chemically modified analogues.
    Golub LM; Suomalainen K; Sorsa T
    Curr Opin Dent; 1992 Mar; 2():80-90. PubMed ID: 1325849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms.
    Golub LM; Lee HM; Ryan ME; Giannobile WV; Payne J; Sorsa T
    Adv Dent Res; 1998 Nov; 12(2):12-26. PubMed ID: 9972117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs.
    Golub LM; Ramamurthy NS; McNamara TF; Greenwald RA; Rifkin BR
    Crit Rev Oral Biol Med; 1991; 2(3):297-321. PubMed ID: 1654139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical applications of non-antimicrobial tetracyclines in dermatology.
    Monk E; Shalita A; Siegel DM
    Pharmacol Res; 2011 Feb; 63(2):130-45. PubMed ID: 20937386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Chemically Modified Tetracyclines in the Management of Periodontal Diseases: A Review.
    Ghangurde AA; Ganji KK; Bhongade ML; Sehdev B
    Drug Res (Stuttg); 2017 May; 67(5):258-265. PubMed ID: 28268238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blocking periodontal disease progression by inhibiting tissue-destructive enzymes: a potential therapeutic role for tetracyclines and their chemically-modified analogs.
    Rifkin BR; Vernillo AT; Golub LM
    J Periodontol; 1993 Aug; 64(8 Suppl):819-27. PubMed ID: 8410621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tetracyclines: nonantibiotic properties and their clinical implications.
    Sapadin AN; Fleischmajer R
    J Am Acad Dermatol; 2006 Feb; 54(2):258-65. PubMed ID: 16443056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating periodontal diseases by blocking tissue-destructive enzymes.
    Golub LM; Wolff M; Roberts S; Lee HM; Leung M; Payonk GS
    J Am Dent Assoc; 1994 Feb; 125(2):163-9; discussion 169-71. PubMed ID: 8113524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COL-3 benefits patients with AIDS-related Kaposi's sarcoma.
    Furlow B
    Lancet Oncol; 2006 May; 7(5):368. PubMed ID: 16696161
    [No Abstract]   [Full Text] [Related]  

  • 15. Functional sites of chemically modified tetracyclines: inhibition of the oxidative activation of human neutrophil and chicken osteoclast pro-matrix metalloproteinases.
    Sorsa T; Ramamurthy NS; Vernillo AT; Zhang X; Konttinen YT; Rifkin BR; Golub LM
    J Rheumatol; 1998 May; 25(5):975-82. PubMed ID: 9598901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-antibacterial tetracycline formulations: host-modulators in the treatment of periodontitis and relevant systemic diseases.
    Golub LM; Elburki MS; Walker C; Ryan M; Sorsa T; Tenenbaum H; Goldberg M; Wolff M; Gu Y
    Int Dent J; 2016 Jun; 66(3):127-35. PubMed ID: 27009489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature.
    Griffin MO; Fricovsky E; Ceballos G; Villarreal F
    Am J Physiol Cell Physiol; 2010 Sep; 299(3):C539-48. PubMed ID: 20592239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Nonantimicrobial effects of tetracyclines].
    García-Alvarez L; Oteo JA
    Rev Esp Quimioter; 2010 Mar; 23(1):4-11. PubMed ID: 20232018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model.
    Lokeshwar BL; Selzer MG; Zhu BQ; Block NL; Golub LM
    Int J Cancer; 2002 Mar; 98(2):297-309. PubMed ID: 11857423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CMT-3. CollaGenex.
    Fingleton B
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1460-7. PubMed ID: 14763133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.